The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) was released in late 2021. The adoption of new tumor nomenclature, grading criteria, terminology, tumor types, and novel diagnostic approaches, including methylation profiling, will benefit the precise diagnosis of CNS tumors, facilitate optimal patient care and improve diagnostic reproducibility with higher clinical relevance. However, the gap between rapid updates in tumor classification and the clinical management of patients requires frequent and up-to-date communications between neuropathologists and clinicians. This review aims to provide an overview of WHO CNS5, focused on the changes that are most pertinent to the clinical care of patients. Forming concrete ideas for neuropathologists that are necessary to express to clinicians, for a better understanding of how the patient may benefit from the new classification.

Glioma is a highly heterogeneous disease with yet unknown mechanisms. It is imperative to provide individualized and precise treatment based on the multidisciplinary diagnosis and treatment model and the basic principles of evidence-based medicine for these patients. In 2018, the Glioma Society Affiliated to Chinese Medical Doctor Association led the development of the "Chinese Expert Consensus on Multidisciplinary Team (MDT) Management of Glioma," which significantly promoted the application of the MDT approach in China. To standardize the diagnosis and treatment of MDT for glioma in different regions and grades of hospitals, we plan to update the "Chinese Expert Consensus on MDT Management of Glioma" based on the currently available evidence-based medical evidence. This new version will update the standards of surgical procedures, clinical management, and quality control for the implementation of MDT for glioma to provide guidelines and recommendations for clinicians. The Consensus Committee will follow the policies of the Evidence-Based Clinical Practice Guidelines development, form a multidisciplinary expert team, and utilize Evidence-Based Management in line with the Oxford University Center for Evidence-Based Medicine Levels of Evidence and Grades of Recommendation to develop the evidence-based expert consensus on MDT for glioma. The proposal emphasizes the significance, purpose, members of the Consensus Committee, identification of clinical problems, evidence acquisition, evaluation and integration, and recommendation generation.